Arcutis : ZORYVE Cream 0.15% Improves Atopic Dermatitis Across Skin Types In Phase 3 Trials
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Arcutis Biotherapeutics Inc.’s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ethnicity, and Fitzpatrick skin types, as per subgroup analysis results from the Phas
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1737291285-9d716e771ad849e1b7938a09f8b1a94e.jpg "How to Find the Best Mortgage Rates")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1803777103-b9626d35c9fd4424ae7ecc3b6d58a558.jpg "Accountant Career Path and Qualifications")
:max_bytes(150000):strip_icc():format(jpeg)/AFFLUENT.MILLENNIAL.HERO.GettyImages-868506558_2600-84706e45802340b1865d4b49c285a662.jpg "The Affluent Millennial Investing Survey")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2151279555-f38549a64433496982ff93944b309afb.jpg "5 Transamerica Mutual Funds to Consider")